Get the Stockscreener App
1.38
0.72%
-0.01
Ikena Oncology Inc stock is traded at $1.38, with a volume of 40,273.
It is down -0.72% in the last 24 hours and down -1.43% over the past month.
Ikena Oncology Inc is a targeted oncology company developing precision therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the Hippo and RAS onco-signaling network. Its targeted oncology product candidate, IK-930, is an oral small-molecule inhibitor of the transcriptional enhanced associate domain, or TEAD, a transcription factor in the Hippo signaling pathway, a known oncogenic pathway that also drives resistance to multiple targeted and chemotherapies. Its other product candidates are IK-175 and IK-595.
See More
Previous Close:
$1.39
Open:
$1.388
24h Volume:
40,273
Relative Volume:
0.41
Market Cap:
$69.97M
Revenue:
$9.16M
Net Income/Loss:
$-68.17M
P/E Ratio:
-0.8466
EPS:
-1.63
Net Cash Flow:
$-80.16M
1W Performance:
+3.76%
1M Performance:
-1.43%
6M Performance:
-11.54%
1Y Performance:
-16.36%
1-Day Range:
$1.35
$1.4015
1-Week Range:
$1.31
$1.42
52-Week Range:
$0.9707
$1.94
Ikena Oncology Inc Stock (IKNA) Company Profile
Name
Ikena Oncology Inc
Sector
Industry
Phone
857-343-8292
Address
50 NORTHERN AVE., BOSTON
Compare IKNA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IKNA
Ikena Oncology Inc
|
1.38 | 69.97M | 9.16M | -68.17M | -80.16M | -1.63 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.85 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
567.74 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
314.94 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
560.24 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
250.30 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Ikena Oncology Inc Stock (IKNA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-29-24 | Downgrade | Wedbush | Outperform → Neutral |
| Sep-22-23 | Initiated | Wedbush | Outperform |
| May-04-23 | Resumed | H.C. Wainwright | Buy |
| Dec-23-21 | Initiated | H.C. Wainwright | Buy |
| May-05-21 | Resumed | Credit Suisse | Outperform |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Apr-20-21 | Initiated | Credit Suisse | Outperform |
| Apr-20-21 | Initiated | Jefferies | Buy |
| Apr-20-21 | Initiated | William Blair | Outperform |
View All
Ikena Oncology Inc Stock (IKNA) Latest News
Two Sigma Investments LP Sells 55,935 Shares of Ikena Oncology, Inc. (NASDAQ:IKNA) - Defense World
Squarepoint Ops LLC Acquires Shares of 43,640 Ikena Oncology, Inc. (NASDAQ:IKNA) - Defense World
Millennium Management LLC Trims Stake in Ikena Oncology, Inc. (NASDAQ:IKNA) - Defense World
Citadel Advisors LLC Lowers Position in Ikena Oncology, Inc. (NASDAQ:IKNA) - Defense World
Two Sigma Advisers LP Has $258,000 Stock Holdings in Ikena Oncology, Inc. (NASDAQ:IKNA) - Defense World
Ikena Oncology, Inc. (NASDAQ:IKNA) Shares Bought by Northern Trust Corp - Defense World
BNP Paribas Financial Markets Acquires New Position in Ikena Oncology, Inc. (NASDAQ:IKNA) - Defense World
Ikena Oncology Reports Q1 Loss Amid Merger Plans - TipRanks
Ikena Oncology Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Ikena Oncology, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
Ikena Oncology, Inc. SEC 10-Q Report - TradingView
Renaissance Technologies LLC Sells 70,400 Shares of Ikena Oncology, Inc. (NASDAQ:IKNA) - Defense World
Geode Capital Management LLC Purchases 56,936 Shares of Ikena Oncology, Inc. (NASDAQ:IKNA) - Defense World
Marquis Who's Who Honors Wilmin P. Bartolini for Expertise in Pharmaceutical Consulting - 24-7 Press Release Newswire
Prudential Financial Inc. Trims Holdings in Ikena Oncology, Inc. (NASDAQ:IKNA) - Defense World
Ikena Oncology stock hits 52-week low at $0.98 amid market challenges - Investing.com Canada
Ikena Oncology stock hits 52-week low at $0.98 amid market challenges By Investing.com - Investing.com South Africa
Ikena Oncology stock hits 52-week low at $1.21 amid market challenges - Investing.com
Ikena Oncology stock hits 52-week low at $1.21 amid market challenges By Investing.com - Investing.com South Africa
Ikena Oncology Announces Closing of Initial Public Offering and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares - Business Wire
Ikena Oncology: Investor Caution as Dividend Payments Remain Unlikely - TipRanks
Ikena Oncology Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Ikena Oncology Inc expected to post a loss of 19 cents a shareEarnings Preview - TradingView
Ikena Oncology, Inc. SEC 10-K Report - TradingView
Short Interest in Ikena Oncology, Inc. (NASDAQ:IKNA) Decreases By 11.8% - MarketBeat
Discovering February 2025's Promising Penny Stocks On US Exchanges - Simply Wall St
Ikena Oncology (NASDAQ:IKNA) Stock Price Down 0.7%Here's Why - MarketBeat
A History of Outperforming Analyst Forecasts and Beating the Odds: Ikena Oncology Inc (IKNA) - SETE News
Understanding the Risks of Investing in Ikena Oncology Inc (IKNA) - Knox Daily
Ikena Oncology Merger with Inmagene Biopharmaceuticals and Private Placement Financing - Leerink Partners
Jane Street Group LLC Sells 18,570 Shares of Ikena Oncology, Inc. (NASDAQ:IKNA) - Defense World
Geode Capital Management LLC Acquires 14,319 Shares of Ikena Oncology, Inc. (NASDAQ:IKNA) - Defense World
How former leaders of a sold-off biotech company landed their drugs again - The Business Journals
Deal Watch: Regeneron Quietly Acquires UK Ophthalmology Firm Oxular - insights.citeline.com
US Penny Stocks To Watch In January 2025 - simplywall.st
Ikena Oncology (IKNA) Moves to Buy: Rationale Behind the Upgrade - MSN
Ikena Oncology and Inmagene Biopharmaceuticals to Merger - citybiz
Five things you need to know, and a Chrismukkah throwback - The Business Journals
Ikena Oncology, Inc. (NASDAQ:IKNA) Shares Purchased by Fmr LLC - Defense World
Boston biotech opts for reverse merger with San Diego company - The Business Journals
Ikena Oncology and Inmagene Biopharmaceuticals announces merger - MSN
Ikena, after tough year of layoffs, merges with Inmagene to focus on phase 2 dermatitis prospect - Fierce Biotech
3 US Penny Stocks With Market Caps Over $40M To Consider - Yahoo Finance
Ikena Oncology Third Quarter 2024 Earnings: US$0.21 loss per share (vs US$0.40 loss in 3Q 2023) - Yahoo Finance
Ikena Oncology Reports Third Quarter 2024 Financial Results - GlobeNewswire
Ikena Oncology Reports Second Quarter 2024 Financial Results - GlobeNewswire
Ikena Oncology expands role of CFO Jotin Marango to COO - Investing.com
Ikena Oncology - The Pharma Letter
Cancer biotech lays off more employees in 2024, begins hunt for 'strategic options' - The Business Journals
UPDATE – Ikena Oncology Announces Strategic Update - GlobeNewswire
Ikena Oncology Reports First Quarter 2024 Financial Results and Corporate Update - GlobeNewswire
Ikena Oncology Inc Stock (IKNA) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.10%
1.57%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):